The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -5,407,470 | -12,266,429 |
| Stock-based compensation expense | 1,800,614 | 2,704,372 |
| Change in estimated fair value of warrant liability | 0 | 0 |
| Gain on settlement of warrant liability | 0 | - |
| Loss on issuance of related party convertible notes payable at fair value | 0 | 0 |
| Change in estimated fair value of related party convertible notes payable | 0 | 0 |
| Interest accrued on license payable | 15,188 | - |
| Prepaid assets and other current assets | 323,334 | -370,375 |
| Other assets | 0 | -110,548 |
| Accounts payable | -1,828,207 | 1,130,116 |
| Accrued compensation | -541,835 | 499,669 |
| Accrued interest | -81,082 | 10,125 |
| Other accrued expenses | -311,583 | -1,351,277 |
| Net cash used in operating activities | -6,677,709 | -8,792,501 |
| Proceeds from issuance of shares of common stock under underwritten public offering, net of underwriting discounts and offering costs | 15,573,966 | - |
| Proceeds from issuance of shares of common stock under june 2025 private placement, net | -29,084 | 4,621,546 |
| Proceeds from issuance of shares of common stock under the committed equity facility, net | 1,663,236 | 2,163,100 |
| Proceeds from initial public offering, net of underwriting discounts and commissions | 0 | - |
| Payment of offering costs related to initial public offering | 0 | - |
| Proceeds from issuances of related party convertible notes payable | 0 | 0 |
| Proceeds from issuance of related party short-term loan | 0 | - |
| Payment of related party short-term loan | 0 | - |
| Proceeds from the exercise of stock options | 0 | 34,115 |
| Deferred offering costs | 98,302 | 175,226 |
| Net cash provided by financing activities | 17,109,816 | 6,643,535 |
| Net change in cash and cash equivalents | 10,432,107 | -2,148,966 |
| Cash and cash equivalents at beginning of period | 8,641,622 | - |
| Cash and cash equivalents at end of period | 16,924,763 | - |
ACTUATE THERAPEUTICS, INC. (ACTU)
ACTUATE THERAPEUTICS, INC. (ACTU)